Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023)
Pyxis Oncology's (PYXS) quarterly Receivables - Other came in at $21000.0 in Q4 2023, down 96.49% year-over-year from $598000.0 in Q4 2022, and down 96.49% quarter-over-quarter from $598000.0 in Q4 2022.
Powered by 
Analysis
Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023) Analysis & Trends
Pyxis Oncology (PYXS) has reported Receivables - Other for 2 consecutive years, with $21000.0 the latest figure, recorded in Q4 2023.
- On a quarterly basis, Receivables - Other fell 96.49% year-over-year to $21000.0 in Q4 2023; TTM through Dec 2023 was $21000.0, a 96.49% decrease from a year earlier, with the FY2023 full-year figure at $21000.0, down 96.49% from the prior year.
- Receivables - Other was $21000.0 for Q4 2023 at Pyxis Oncology, down from $598000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $598000.0 in Q4 2022 and troughed at $21000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Pyxis Oncology | 208.61 Mn | 175.62 Mn | - |